MEK inhibitors
Immuneering Takes Lead Agent Into Phase II Trial Betting on Universal RAS Inhibition in Solid Tumors
Premium
The firm is evaluating IMM-1-104 in the Phase IIa portion of a trial involving patients with pancreatic cancer and RAS-mutant melanoma and NSCLC.
Erasca, Novartis Ink Deal to Study Mekinist, Naporafenib Combo in RAS/MAPK-Driven Cancers
Novartis will provide Mekinist for Erasca's SEACRAFT-1 and SEACRAFT-2 trials in RAS Q61X-mutant solid tumors and NRAS-mutant melanoma, respectively.
FDA Approves Pfizer's Braftovi-Mektovi Combo, Foundation Medicine Tests for BRAF-Mutant NSCLC
The BRAF and MEK inhibitors were approved alongside Foundation Medicine's liquid biopsy and solid tumor companion tests based on Phase II PHAROS trial results.
Erasca Starts Tissue-Agnostic Trial of RAF/MEK Combination Therapy
The firm will study the activity of its pan-RAS inhibitor naporafenib with Novartis' MEK inhibitor Mekinist in RAS Q61X-mutated solid tumors.
Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients
Premium
Results from the DreamSeq trial showed that more melanoma patients who received frontline immunotherapy were alive at two years compared to frontline targeted therapy.